Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
U.S. Stock Futures Rise as Markets Brace for Jobs and Inflation Data 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nikkei 225 Hits Record High Above 56,000 After Japan Election Boosts Market Confidence 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
Eli Lilly, an American pharmaceutical company, headquartered in Indianapolis, Indiana, issued a recall on a batch of its Glucagon Emergency Kits late last month. This is a type of therapy for diabetic patients experiencing an emergency situation.
According to Reuters, it turned out that the recalled emergency kit was manufactured at its factory plant in Indiana. The location is quite controversial because it was cited by the U.S. Food and Drug Administration this year for quality control issues, including substandard sanitation.
The health regulators inspected the said Eli Lilly plant and found violations related to quality control in the manufacturing of some of its products. Thus, with the recall, it was unavoidable for some to think that it may be connected to the unhygienic plant. Then again, there is no proof for this.
At any rate, Eli Lilly issued the voluntary recall on one batch of its Glucagon Emergency Kit on Sept. 25, and the FDA published the notice on Sept. 26. The health regulator indicated “loss of potency” as the reason for the recall. Moreover, Lilly was also said to have issued a recall in Canada as well.
The pharmaceutical firm recalled the said kits after receiving a report involving a patient who experienced seizures even after being injected with the drug. This is said to be a situation that indicates the treatment is not potent enough to provide relief or to work as it should. Based on the report, Eli Lilly said the failure could be due to the manufacturing process, but it did not specify or elaborate what exactly the main issue could be.
The drug is mainly used for the treatment of diabetes patients with dangerously low blood sugar. It was described as an anti-hypoglycemic agent and a gastrointestinal motility inhibitor for the treatment of severe hypoglycemia in patients with diabetes mellitus.
Meanwhile, in response to inquiries about the place of production for the recalled product, Eli Lilly confirmed to Reuters that the affected Glucagon Emergency Kit lots were indeed made at its Indianapolis facility. It added that the recalled drug had been distributed in Canada. Around 66,000 units were affected by the recall, and some 19,000 were distributed in the U.S. and Canada.
